TumorGenesis Inc. specializes in media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. With this tool, researchers are able to expand and study cancer cell types inherent in blood tumors and organ systems of all mammals, including humans. This platform, along with other proprietary FDA-approved technologies from Helomics, is used to fuel unique and more clinically actionable data for our predictive models.
Let us tell you about TumorGenesis.
TumorGenesis will transform cancer diagnosis and treatment via a three-pronged approach: our unique media, discovery kits and AI.
By “fooling” cancer cells into behaving as if they are in a patient’s body, we help research to be more effective to human response. AI enables us to link our patient-derived tumors to patient therapies faster than humanly possible otherwise.
What problems do we solve?
TumorGenesis makes living tumors readily available to researchers.
At TumorGenesis we search for cancer cell variants and can isolate and grow them without significantly impacting their signatures. Once isolated, the separated sub clonal colonies can be recombined to study drug interactions, cross talk, and unique opportunities for exploitation. The goal is to provide the best home for the cancer cells that includes the right media, the right matrix, and the right biomarkers. Give us a call to discuss how TumorGenesis researchers can help you zero in on meaningful information from cancer cells that will translate to patient treatment.
What are our major offerings?
TumorGenesis provides the fastest and most effective means to develop tumors for research study. Our portfolio of 25 ovarian cancer cell lines covers more than 90% of all documented strains of this disease.